Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.53 |
| ▸ | CSF1R | P07333 | 4/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL97179 | 0.99 | BRAF (0.52) | BRAFCSF1RKITRAF1PDGFRB | |
| SCHEMBL1658803 | 0.86 | SMN1; SMN2 (0.51) | BRAFCSF1RKITRAF1PDGFRB | |
| SCHEMBL97455 | 0.84 | SMN1; SMN2 (0.51) | BRAFCSF1RKITRAF1PDGFRB | |
| SCHEMBL7602223 | 0.82 | SMN1; SMN2 (0.45) | MAPK14SMN1; SMN2ALDH1A1MAPT | |
| Nitric Acid SCHEMBL1408807 | 0.80 | BRAF (0.64) | BRAFCSF1RKITRAF1PDGFRB | |
| SCHEMBL1358516 | 0.79 | BRAF (0.56) | BRAFCSF1RKITRAF1PDGFRB | |
| SCHEMBL100510 | 0.78 | MAPT (0.57) | SMN1; SMN2ALDH1A1MAPT | |
| Nitric Acid SCHEMBL1448510 | 0.76 | CSF1R (0.47) | BRAFCSF1RKITRAF1PDGFRB | |
| SCHEMBL1408852 | 0.74 | CSF1R (0.57) | BRAFCSF1RKITMAPK14KDM4E | |
| SCHEMBL1409060 | 0.74 | BRAF (0.61) | BRAFCSF1RKITRAF1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426119-B1 | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3- (4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | NATCO PHARMA LTD (IN) | 2013-10-09 | — | — | EP | claimed |
| EP-2426119-A1 | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3- (4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | Natco Pharma Limited (IN) | 2012-03-07 | — | — | EP | claimed |
| US-7939541-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agent | NATCO PHARMA LIMITED (IN) | 2011-05-10 | — | — | US | claimed |
| JP-2011513379-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2254882-A2 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3- (4-PYRIDIN-3-YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | Natco Pharma Limited (IN) | 2010-12-01 | — | — | EP | claimed |
| WO-2009109866-A2 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3- (4-PYRIDIN-3-YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2009-09-11 | — | — | WO | claimed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | claimed |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2008-10-09 | — | — | US | claimed |
| CN-102046617-B | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | NATCO PHARMA LTD | 2014-08-20 | — | — | CN | disclosed |
| EP-2426119-B1 | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3- (4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | NATCO PHARMA LTD (IN) | 2013-10-09 | — | — | EP | disclosed |
| EP-2426119-B1 | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3- (4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide | NATCO PHARMA LTD (IN) | 2013-10-09 | — | — | EP | disclosed |
| EP-2254882-B1 | USE OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL -3-(4-PYRIDIN-3-YL-PYRIMIDIN-2YL-AMINO)-PHENYL]-BENZAMIDE AGAINST BREAST CANCER, GLIOMA AND ANGIOGENESIS. | NATCO PHARMA LTD (IN) | 2012-07-18 | — | — | EP | disclosed |
| EP-2254882-B1 | USE OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL -3-(4-PYRIDIN-3-YL-PYRIMIDIN-2YL-AMINO)-PHENYL]-BENZAMIDE AGAINST BREAST CANCER, GLIOMA AND ANGIOGENESIS. | NATCO PHARMA LTD (IN) | 2012-07-18 | — | — | EP | disclosed |
| US-8183253-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents; chronic myeloid leukemia | NATCO PHARMA LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| WO-2009109866-A2 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3- (4-PYRIDIN-3-YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109866-A2 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3- (4-PYRIDIN-3-YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2009-09-11 | — | — | WO | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2008-10-09 | — | — | US | disclosed |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | ABL1, ABL2, BCR | BRAF 35/4885CSF1R 576/4885KIT 189/4885 |
| US-20080249121-A1 | INTERMEDIATES AND A PROCESS EMPLOYING THE INTERMEDIATES FOR THE PREPARATION OF (3-TRIFLUOROMETHYLSULFONYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | AZI2, NNMT, ALKBH2 | BRAF 692/4885CSF1R 2056/4885KIT 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.